Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
EVE Health Group Limited ( (AU:EVE) ) has shared an announcement.
EVE Health Group Limited has announced its acquisition of Nextract, an Australian biotech company specializing in advanced oral delivery systems for regulated health markets. This strategic move allows EVE to enter the global erectile dysfunction and dysmenorrhea markets, valued at $5.3 billion and $10.9 billion respectively. The acquisition, valued at $3 million in equity, is supported by a capital raising plan and a 40:1 share consolidation. The integration of Nextract’s capabilities is expected to enhance EVE’s technical expertise and broaden its strategic initiatives. The company is targeting regulatory submissions for Nextract’s lead products by late 2025, with commercial launches anticipated in Q4 2025. The acquisition also positions EVE to tap into the MENA region’s growing demand for high-quality, alcohol-free health products.
More about EVE Health Group Limited
EVE Health Group Limited is a company operating in the health, nutrition, and wellness industry. It focuses on providing health solutions through innovative formulations and direct-to-consumer platforms. The company is expanding its operations into regulated pharmaceutical and clinical health channels, leveraging its expertise in wellness operations.
Current Market Cap: A$5.27M
Find detailed analytics on EVE stock on TipRanks’ Stock Analysis page.